Posted by Michael Wonder on 17 Mar 2026
Polaryx Therapeutics receives FDA fast track designation for PLX‑200 for late‑infantile neuronal ceroid lipofuscinosis
17 March 2026 - Regulatory milestone supports advancement of the SOTERIA Phase 2 basket trial evaluating PLX‑200 across multiple lysosomal storage disorders.
Polaryx Therapeutics today announced that the US FDA has granted fast track designation to PLX-200 for the treatment of late-infantile neuronal ceroid lipofuscinosis.
